Part 2 of our CBD Beyond The Hype series
Since Congress passed the 2018 Farm Bill (legalizing Hemp/CBD at the Federal level), consumers have been bombarded with information about the benefits and risks related to usage of CBD. We have seen many articles written about the lack of scientific proof that CBD works for its many touted benefits. Part of the “lack of proof” comes from the fact that the research in the US has been generally non existent for medical use of cannabis.
The Godfather of Medical Cannabis Research
Israel is where the majority of research on cannabis has taken place. It started with Raphael Mechoulam’s discovery of THC and its psychoactive properties in 1964 Mechoulam. Mechoulam and his team later discovered the endocannabinoid system (ECS) which is the largest receptor system in the human body. We know that THC impacts the CB1 and CB2 receptors to create the “high”, but we know less about how CBD works to help regulate our ECS. CBD is thought to have a broader impact on getting the body back to homeostasis by increasing our bodies own cannabinoids, binding with our serotonin receptors and stimulating receptors that help calm the nervous system. Dr. Yasmine Hurd (Mount Sinai in NY) said it well. “The brain is about a symphony” and CBD “brings the symphony into harmony” (NY Times- Can CBD Really Do All That?).
What Does The World Health Organization Say About Safety?
“In humans, CBD exhibits no effects indicative of any abuse or dependence potential”
“There is also preliminary evidence that CBD may be a useful treatment for a number of other medical conditions.”
“CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications.”
CBD seems to have some positive relationship with our endocannabinoid system and while we do not fully understand exactly how they interact, there is some scientific evidence and significant anecdotal evidence to support potential health benefits. Since safety concerns are very low with CBD, it is not surprising that consumers are jumping on board before all of the evidence is proven.